DrugMap: A quantitative pan-cancer analysis of cysteine ligandability
Mariko Takahashi, Harrison Byron Chong, Siwen Zhang, Tzu-yi Yang, Matthew J. Lazarov, Stefan Andrew Harry, Michelle Maynard, Brendan J. Hilbert, Ryan D. White, Heather E. Murrey, Chih‐Chiang Tsou, Kira Vordermark, Jonathan Assaad, Magdy Gohar, Benedikt R. Dürr, , Liron Bar‐Peled
DrugMap quantitatively analyzes cysteine ligandability across 416 cancer cell lines, revealing redox state, conformational changes, and mutations as drivers of variability, and identifies covalent inhibitors targeting NFκB1 and SOX10.
Cell · Apr 22, 2024Peer-reviewedSystems Biology